We previously showed that mice with a null mutation in syndecan-1 (Sdc1; CD138) were resistant to Wnt1-induced mammary tumor initiation. The absence of Sdc1 inhibited the increase in the mammary stem cell fraction that is characteristic of preneoplasia in this model. As the tumor precursor cells are recruited from the stem/ progenitor cell compartment, tumor development was also inhibited (Liu et al., 2004; PNAS 101, 4158). Although Sdc1À/À mice are grossly normal, they are systemically smaller, suggesting that developmental abnormalities may extend further than their mammary glands. We have therefore evaluated the multi-organ response of Sdc1À/À mice to carcinogen-induced tumor development (7,12-dimethylbenz[a]anthracene, DMBA), and find these mice to be resistant to tumorigenesis in all the predominant carcinogen-susceptible lineages. Thus, Sdc1À/À mice administered DMBA during juvenile development are resistant not only to epithelial tumors, including liver (60-80%) and lung tumors (C57BL6 mice, 60-80%), but also to lymphoma (over 70%, depending upon strain and carcinogen dose). We demonstrate that CD138 is expressed (heterogeneously) in the hematopoietic stem cell fraction (and not only in pre-B and plasma cells), and that tumors arise in both myeloid and lymphoid lineages. Furthermore, carcinogen-induced mammary tumors are bilineal, implying a bipotent precursor cell. Both observations imply that the DMBA-induced tumor precursor cells are drawn from the stem/progenitor fraction, and we suggest that pathogenic activation of these cells could be abnormal in Sdc1À/À mice.
Introduction
Syndecan-1 (Sdc1; CD138) is an abundant heparan sulfate proteoglycan expressed by most epithelial cells, and some other cells (including pre-B and plasma cells). Its function in vitro appears to be dominated by the heparan sulfate side chains, which participate in growth factor signaling by promoting ligand/receptor complex formation (Bernfield et al., 1999; Whitelock and Iozzo, 2005) . Despite its abundant expression and early expression during development, Sdc1À/À mice are viable and fertile, although their pathologic responses are affected, including those involved in skin wound healing, microbial pathogenesis in the lung and leukocyte adhesion (Park et al., 2001; Gotte et al., 2002; Stepp et al., 2002; Taylor and Gallo, 2006) . The fact that mice with a constitutive mutation of Sdc1 show such subtle alterations of phenotype appears to contradict the substantial roles ascribed to this molecule in cultured cells. For Sdc1À/À mammary epithelial cells, we have shown that heparan sulfate function is rescued by compensatory conjugation of heparan sulfate side chains to other core proteins (Liu et al., 2003) . The phenotype of these mice is therefore likely to be dominated by functions of the core protein that cannot be substituted by generic cell surface heparan sulfate core proteins (Kramer and Yost, 2003) .
We have previously described a developmental phenotype in these mice that is associated with decreased tumor susceptibility. Sdc1À/À mammary glands are hypomorphic from embryogenesis through adulthood, with 50% fewer terminal end buds. Mammary end buds lead the extension of the developing ductal tree, and are widely considered to be the source of ductal stem cell activity (Kenney et al., 2001) . Flow cytometric fractionation of dissociated cells from virgin adult Sdc1À/À ductal trees showed there were fewer cells in mammary progenitor-enriched fractions (Liu et al., 2004) , and these glands showed a hypomorphic response to Wnt-induced stem cell amplification. Furthermore, we have shown that the overall differentiation of the mammary epithelial cell population is altered, so that only half the normal number of cells are Wnt responsive. To predict the effect of underactive mammary stem cells upon mammary development, we have simulated organogenesis using a mathematical model (Paguirigan et al., 2006) , and showed that the principle outcomes should be slowed population expansion (organogenesis), lower equilibrium stem/progenitor fractions and altered differentiation of the cell majority. All of these effects we have begun to document in vivo and in vitro.
In this study, we examined the response of Sdc1À/À mice to carcinogen-induced tumorigenesis. Polycyclic aromatic hydrocarbons (PAHs) are prominent environmental carcinogens (in cigarette smoke for example) that induce DNA mutations (GC-TA and AT-TA transversions). A synthetic PAH, DMBA (7,12-dimethylbenz[a] anthracene) has been used extensively to induce breast tumors in rodent models, and this model is used as the 'gold standard' to evaluate potential therapeutic modalities (Mehta, 2000) . This carcinogen also induces tumors in rodents in other organs, when administered during juvenile development, principally for lung, liver and the hematopoietic lineages (Walters, 1966; Flaks, 1968; Roe and Walters, 1968; Akamatsu, 1975; Heidel et al., 2000) .
Here, we report that Sdc1À/À mice are profoundly resistant to tumor induction in all the major lineages susceptible to DMBA (and other mutagenic carcinogens). The fact that tumor resistance is widespread and is shared between epithelial and hematopoietic lineages suggests that these tissues share a common, Sdc1-dependent tumorigenic pathway. We describe when and where these mice show altered tumorigenesis, and propose a mechanism that could explain our observations.
Results
Sdc1À/À mice are systemically smaller Sdc1À/À mice are systemically smaller than their wildtype sibling mice (decreased by 15%70.4 for BALB/c; 13%70.4 for C57BL/6; Figure 1a ). As mammary ductal development is impaired in these mice (Liu et al., 2003) , we considered the possibility that altered lactation could slow postnatal growth. We therefore tested embryo size in pregnant Sdc1 þ /À BALB/c females (mated to Sdc1 þ /À males). E17.5d Sdc1À/À embryos were also 15% smaller than wild-type siblings (Figure 1b ). This suggests that these mice have a systemic growth defect throughout their development.
Administration of DMBA to juvenile Sdc1À/À mice To test whether these mice showed generalized alterations in their tumor susceptibility, 12-day-old pups (both males and females, BALB/c and C57BL/6 strains) were administered DMBA at two doses (0.1 and 0.01 mmol/g), and housed for 32 weeks.
Thirty-two percent of C57BL/6 mice, and 24% of BALB/c mice were morbid pre-term. Sdc1À/À mice from both strains were highly resistant to DMBAinduced morbidity (Figure 2a ). Morbid mice had enlarged spleens or thymus glands, and flow cytometric analysis of the affected tissues typed the prevalent disease as a precursor-T-cell lymphoblastic lymphoma, and less commonly, as a myeloproliferative process progressing to an erythroleukemia .
This phenotype was surprising given that CD138 expression has been reported only for pre-B and plasma cells, and is used as a diagnostic marker for human plasma cell myeloma. We evaluated the expression of CD138 in normal bone marrow cells, and specifically in a hematopoietic stem and progenitor-enriched fraction (isolated by flow cytometry using Sca1 þ , Kit1 þ and LinÀ criteria). Nearly half of this population was positive for CD138 (measured by comparing normal stem/progenitor fractions with the same fraction isolated from CD138À/À mice; Figure 3a ). As expected (from other reports), CD138 expression was not found on normal T-cell progenitors in the thymus, or on more differentiated myeloid lineage progenitors (data not shown).
In order to more precisely define which cells in this fraction expressed Sdc1, bone marrow cells were sorted using their expression of cell surface markers that characterize long-term hematopoietic stem cell BALB/c:Sdc1À/À; C57BL/6; and C57BL/ 6:Sdc1À/À (b) E17.5 embryos from Sdc1 þ /À females impregnated by Sdc1 þ /À males (BALB/cJ, N6) were removed, separated from placenta and yolk sac, genotyped and weighed. Sdc1À/À embryos weighed 15% less (*P-value o0.00004).
Sdc1 null mice resist DMBA-induced tumor development SP McDermott et al (LT-HSCs), short-term (ST) HSCs, multipotent progenitors and other more restricted lineage-specific progenitor cells (Figure 3b ). Sdc1 was expressed by approximately 50% of LT-HSC, the majority of STHSCs and almost all multipotent progenitors (MPPs), but none of the specific lineage progenitors. This is consistent with the Sdc1 expression pattern detected by transcriptional profiling of similarly purified fractions (Forsberg et al., 2005) , and suggests that Sdc1 expression is induced upon maturation and differentiation of LT-HSCs. Functional characterization of CD138 þ and CD138À sub-populations derived from the LT-HSCenriched cell fraction (assayed by transplantation into irradiated hosts) showed that CD138 þ cells, although multipotent, were not long lived, and their myeloid progeny disappeared several weeks after reconstitution (Figure 3c ). We conclude that the CD138 þ fraction of this 'LT-HSC' sub-population (as defined by LinKit þ Sca þ Thy1.1 lo ) (Morrison and Weissman, 1994) do not have self-renewal capacity and are similar to the ST-HSC/MPP population.
After 32 weeks, all mice were killed and evaluated for gross symptoms of disease. Surface lesions of liver were reduced by 60-80% in Sdc1À/À mice, depending upon dose and strain, and microscopic pathologic evaluation typed the lesions as adenomas and adenocarcinomas ( Figure 4 ). As DMBA is not carcinogenic without metabolic activation (Heidel et al., 2000) , we tested whether Sdc1À/À mice showed a normal metabolic response to DMBA administration. This was especially important, given that the Sdc1 gene is only 17 cM distal to the Aryl hydrocarbon receptor (Ahr) gene on distal chromosome 12. Ahr is a member of the periodic acid/ Schiff (PAS) family of nuclear hormone receptors that induces expression of the P450 genes that metabolize DMBA. We found that the metabolic response of Sdc1À/À livers to DMBA was normal, and conclude that this is unlikely to account for the tumor resistance ( Figure 4c ). Furthermore, Sdc1À/À mice were also protected from tumor development induced by the administration of the direct acting carcinogen, N-ethyl-N-nitrosurea (ENU; Supplementary Figure 1) .
Lung tumor multiplicity was also reduced by 60-80% in C57BL/6 mice. BALBc:Sdc1À/À mice were not protected from lung tumor development. The etiology of this disease was different; this strain developed a much higher tumor load for corresponding carcinogen doses (10-20 Â ; Figure 5 ), and showed highly accelerated tumor progression compared to C57BL/6 mice (Supplementary Figure 1) .
To determine which stage of tumorigenesis was most affected by the absence of Sdc1, the number of prepalpable lesions of lung and liver were counted at early time points after carcinogen administration ( Figure 1A) . Similarly, the number of early, glucose-6-phosphatasenegative lesions was reduced by 50% in C57BL/ 6:Sdc1À/À livers (Supplementary Figure 1B) . These data suggest that the principle effect of Sdc1 is to sustain or promote a very early stage of tumor development in juvenile mice. (There is no morphological evidence for stromal or immune cells in proximity to the preneoplastic liver lesions.) We found that the Sdc1À/À allele does not affect the incidence or rate of mouse mammary tumor virus (MMTV)-induced mammary tumorigenesis (Figure 6a and b). This result was unexpected given that a high fraction of MMTV integration sites activate Wnt loci to induce tumors (van Leeuwen and Nusse, 1995) , and we know that Sdc1 promotes Wnt-initiated tumorigenesis (Alexander et al., 2000) . MMTV-induced disease has a different etiology however, and commences in adulthood when the phenotype of Sdc1À/À mammary glands is minimal. Similarly, when DMBA was administered to adult mice by gavage (a protocol typically used to induce high mammary tumor loads), Sdc1À/À mice showed no resistance (Figure 6c ). In fact, mammary tumors evolved faster in Sdc1À/À mice (Figure 6d ), and these tumors comprised a different morphologic subtype (adenoacanthoma; Figure 7 ). Because these aggressive adenoacanthomas evolve so quickly and predominate, it is not clear whether the development of other tumor types (e.g. ovarian tumors) may have been inhibited in the Sdc1À/À background (Figure 6c) .
DMBA-induced mammary tumors are highly differentiated, like Wnt-induced tumors. The similarity between these tumors was confirmed by immunocytochemical characterization of their mammary cell subtypes (Figure 7 ). Both myoepithelial and luminal cells are present in the cystic adenocarcinomas in control mice. In addition to these characteristically mammary cell types, tumors arising in Sdc1À/À mice also contain keratinizing squamous epithelial cells (resembling skin keratinocytes), showing they retain even the primitive, ectodermal cell fates. This implies that DMBA-induced mammary tumors, like Wnt-induced tumors, are derived from a bipotential precursor cell.
Discussion
Mice with a mutation in Sdc1 are resistant to tumor induction in all lineages affected by carcinogen administration. To date, we have shown that the Sdc1À/À allele is only protective when tissue growth rate is high Cell fractions from HZ mice were gated using the following phenotypes: Sdc1 has been shown to bind specifically to many ligands via its heparan sulfate side chains (including Fgf, Hgf, HB-Egf and IGF-BP5) (Bernfield et al., 1999) and to function as their co-receptor in vitro. However, Sdc1À/À mice do not phenocopy any of the mouse models that have been engineered for loss of function of these signaling pathways. We have previously shown that heparan sulfate is conjugated to other core proteins in Sdc1À/À mice (Liu et al., 2003) , suggesting that this compensatory process could be responsible for the effective rescue of HS-mediated functions. Sdc1 has been variously implicated in processes that impinge upon tumor development, and has been shown to either promote or inhibit tumor development in xenograft or culture models (Bernfield et al., 1999; Whitelock and Iozzo, 2005) . This would suggest that a loss of function could generate highly cell-and tissue-specific phenotypes during tumor initiation and progression. It was therefore striking that Sdc1À/À null mice show such consistent changes, and that these changes characterize not only the epithelial lineages (where Sdc1 expression is constitutive) but also the hematopoietic lineage (where Sdc1 was previously thought to be specifically expressed during a brief and specific phase of B-cell development). We propose that the mechanism that underlies the protection of Sdc1À/À mice from tumor development is not coincidental, but is shared by all these tissue types.
How does this protective mechanism work? Sdc1 has been shown to be induced in stromal cell compartments during embryogenesis, mammary development and wound healing (Sutherland et al., 1991; Gallo et al., 1996; Maeda et al., 2004) . In keeping with this 'reactive' pattern, Sdc1 is frequently expressed by stromal cells associated with breast carcinomas, and promotes growth of MDA-MB-231 breast cancer cells, when overexpressed in stromal cells and co-injected (Maeda et al., 2006) . Sdc1 may modify inflammatory responses to tumor cell growth (Esko et al., 1988) . However, we show that even very early stages of autochthonous liver and lung tumor growth are inhibited in the absence of Sdc1, and that there is little evidence of stromal/ inflammatory activation at these precursor stages ( Figure S1 ). Microenvironmental influences are tailored for specific tissue types, and may be less likely to be shared. It is more attractive to identify a cell-autonomous effect of Sdc1 that could explain these observations.
We therefore speculate that Sdc1 promotes the recruitment of stem/progenitor cells to become tumor precursor cells. We present two lines of evidence that support this idea. Firstly, we show that Sdc1 is specifically expressed by hematopoietic cells exiting the LT-HSC compartment; these remain pluripotent and could serve as reservoirs of DMBA-induced genetic damage. Sdc1 is not expressed by the more restricted normal progenitors that likely constitute the direct cell of origin for the DMBA-induced erythroleukemias and pre-T-cell lymphomas. This expression pattern is supported by recent transcriptional profiling data of HSC cell fractions (Forsberg et al., 2005) . It is not known whether HSCs respond to DMBA administration, and whether a response would include a function for Sdc1 expression.
Secondly, we present data to support a stem/ progenitor precursor for carcinogen-induced mammary tumors. Previously, we have shown that the absence of Sdc1 inhibits the pathogenic accumulation of mammary stem cells in Wnt-induced glands (Liu et al., 2004) . In this case, the tumor precursor cell is recruited from these stem/progenitor cells (Li et al., 2003) , and in Sdc1À/À mice, subsequent tumorigenesis is inhibited. This model serves as a paradigm for stem cell transformation. Here we show that, in common with Wnt-induced mammary tumors, DMBA-induced mammary tumors also contain cells from both mammary lineages, implying a multipotential antecedent. The mammary tumor type, together with the hematopoietic tumor response, suggests that DMBA-induced tumorigenesis may be targeting the stem/progenitor cell compartment.
It is generally accepted that at least some human tumors are likely to arise via subversion of somatic stem cell precursors, exploiting their immortality and division potential. Tumor stem cells (observed in breast, neural and hematopoietic tumors; (Al-Hajj et al., 2003; Singh et al., 2003 Singh et al., , 2004 Huntly and Gilliland, 2005) possess features in common with normal stem cells, although there is no direct proof of their recruitment from somatic stem cell compartments, nor are there data that describe how and why stem cells can be transformed.
Note that not all tumorigenic processes are affected, and these exceptions could be revealing of the protective mechanism for the Sdc1À/À allele. Sdc1À/À tissues are protected during active growth, but adult Sdc1À/À mice show no effect (in response to MMTV infection or DMBA administration). Similarly, when the rates of progression are very high, these mice are not protected, for example, DMBA-or ENU-induced lung tumor development in BALB/c mice, or lung tumor development in C57BL/6:Sdc1À/À mice in response to somatic K-Ras activation (McDermott et al., data not shown). If we assume that the loss of Sdc1 indeed affects stem cell recruitment, then it would be consistent that the effects of Sdc1 should be apparent only when stem/progenitor cells are actively dividing (and able to 'fix' mutations induced by alkylating carcinogens), and when the rate of tumor initiation is limiting.
What is the molecular basis for the observed tumor resistance? The absence of Sdc1 core protein could lead to hypomorphic signaling or adhesion of the tumor precursor cells. Alternatively, gain of heparan sulfate by other core proteins (in the absence of Sdc1) may affect cellular function with the same outcome. When there is compensatory GAG-ylation of other proteins, it becomes difficult to conclusively ascribe the effects of a null mutation to a specific molecular function (Kramer and Yost, 2003) . A third possibility is that the null allele confers tumor resistance that does not depend specifically upon Sdc1 ablation (nonspecific effects of the knockout allele). However, our preliminary data from a culture model suggests that there are specific Sdc1-dependent signaling defects that could account for the developmental and pathologic changes we observe.
We conclude that further analyses of tumor development in Sdc1À/À mice will offer insight into the mechanism underlying their protection from tumor development. If we are correct in deducing that pathogenic stem cell activation is aberrant without Sdc1, these mice will be invaluable in defining exactly how this oncogenic recruitment takes place.
Materials and methods
Reagents/antibodies DMBA (D3254), corn oil (C8267), tricaprylin (T9126), Hoechst-33258 (B2883), b-NADPH (N1630), ethoxyresorufin (E3763) and mouse anti-SMA-Cy3 (C6198, 1. 1 mg/ml) were all from Sigma (St Louis MO, USA). Armenian hamster Figure 5 Sdc1À/À mice resist DMBA-induced lung tumorigenesis. Surface lung tumor multiplicity for the cohorts described in Figures 2 and 3 are shown. C57BL/6 Sdc1À/À mice were 60-80% resistant to lung tumor induction, but BALB/c mice showed no resistance. BALB/c lungs were sectioned and evaluated for their development of all pathologic lesions. These were categorized as adenocarcinomas (AdCA), adenomas (Ad) and hyperplasias (Hy, by the criteria of Nikitin et al. (2004) ; examples shown below), and the proportion of each shown for control and Sdc1À/À lungs.
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anti-MUC1 (Ab-5, clone CT2, 2 mg/ml) was from Neomarkers (Fremont, CA, USA), rabbit anti-cytokeratin 5 (AF-138, 3 mg/ ml) from Covance Research (Berkeley, CA, USA), rabbit anticytokeratin 10 (PRB-159P, 2 mg/ml) and rat anti-cytokeratin 8 (TROMA-1, 8 mg/ml) from Developmental Studies Hybridoma Bank (Iowa City, IA, USA) and fluorescein isothiocyanate (FITC) goat anti-Armenian hamster (127-095-160, 13 mg/ml) from Jackson ImmunoResearch (West Grove, PA, USA). Antibodies used for flow cytometry were anti-CD117 (c-kit)-APC and anti-CD138 (Sdc-1)-phycoerythrin (PE) (BD-Pharmingen, San Diego, CA, USA), anti-Sca1-FITC, anti-CD90.1 (Thy1)-Cy5PE, anti-CD5-PE, anti-B220-APC, anti-CD11b(Mac-1)-FITC (eBioscience, San Diego, CA, USA) and anti-CD3-FITC, anti-CD4-Cy5-PE, anti-CD4-FITC, anti-CD8-APC, anti-Gr1-APC and a cocktail designed to identify differentiated hematopoietic cells, Lin þ (anti-mouse biotinylated anti-CD3, B220, Ter119, Gr-1, Mac1/CD11b), from eBioscience. Secondary antibodies/reagents were Alexa 488-conjugated goat anti-rat antibody (A11006; 4 mg/ml), Alexa 546-goat anti-rabbit (A11010, 8 mg/ml), Alexa405-streptavidin (Molecular Probes-In Vitrogen, Carlsbad, CA, USA) and streptavidin-APC-Cy7 (eBioscience).
Mice and DMBA administration Sdc1À/À mice were generated on a 129S4/SvJae (Alexander et al., 2000; Stepp et al., 2002) and backcrossed onto BALB/cJ and C57BL/6J backgrounds. They were used either at N6 or N10 (as indicated) for these studies. DMBA was administered either by intraperitoneal injection to juveniles, or by gavage to adult females. For intraperitoneal administration, BALB/ cJ:Sdc1À/À (N10, and a control sibling strain) and C57BL/ 6J:Sdc1À/À (N6) mice were used. DMBA was dissolved in tricaprylin (5 or 0.5 mg/ml) and 12-day-old male and female pups (B30 mice/sex/genotype/dose) were injected with 0.01 or 0.1 mmol/g DMBA or with tricaprylin vehicle only. All mice were euthanized and autopsied at 32 weeks. To administer DMBA by gavage to adult females, 13-week-old BALB/ cJ:Sdc1 þ / þ and Sdc1À/À (N6) mice were administered 6 Â 1 mg DMBA (0.2 ml/dose, B250 mg/kg) once a week. Mice were monitored weekly for tumors until morbidity, and analysed for tumor load at necropsy. To obtain gross tumor counts for lung and liver, tumors (white nodules X1 mm) were scored by visual inspection of the surface using a dissecting microscope. Samples were paraformaldehyde-fixed and paraffin-embedded for histopathological evaluation (Cardiff et al., 2000) .
MMTV-induced mammary tumorigenesis
Four-week-old female BALB/c:Sdc1 þ / þ and Sdc1À/À (N6) mice were injected intraperitoneally with MMTV-producing EH23 cells (Shackleford and Varmus, 1988) . Two females per cage were continuously mated to induce maximal expression of MMTV (Shackleford et al., 1993) . Approximately 60 mice per genotype were injected and followed until palpable tumors developed.
Immunohistochemistry
Tissue sections were processed for heat-induced epitope retrieval, blocked with 10% serum for 1 h at room temperature and stained using standard protocols. There were more adenoacanthomas induced by MMTV in Sdc1À/À mice (see below); Sdc1 þ / þ , n ¼ 25, 0% adenoacanthoma, 24% Type A, 72% Type B and 4% Type C adenocarcinoma, compared with Sdc1À/À, n ¼ 23, 9% adenoacanthoma, 30% Type A, 48% Type B and 3% Type C adenocarcinomas. (C) DMBA administration to adult mice. BALB/cJ: Sdc1 þ / þ and Sdc1À/À female mice (n ¼ 30) were dosed with 6 Â 1 mg DMBA by intragastric gavage starting at 13 weeks. When mice became morbid, they were necropsied and gross tumor development recorded; , mammary tumor, , ovarian tumor, , papilloma, , lymphoma and , other disease/unidentified. Mammary tumors (adenoacanthomas; see Figure 7 ) appeared precociously in the Sdc1À/À cohort, shown in (D), a Kaplan-Meier survival analysis of mammary tumor incidence.
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Bone marrow and hematopoietic tumor harvest and flow cytometric analysis Bone marrow cells were obtained from the femurs and tibias of C57BL/6-derived 'HZ' mice (CD45.1 (Ly5.1) þ , Thy1.1; gift of Irving Weissman; Morrison and Weissman, 1994) as described (Ranheim et al., 2005) . Samples from the enlarged spleens of morbid mice were dissociated by trituration. Red blood cells were lysed in hyposmotic ammonium chloride buffer and single-cell suspensions of nucleated marrow cells stained at 41C for 30 min in the indicated antibodies, diluted in phosphate-buffered saline þ 2% fetal calf serum with 4,6-diamidino-2-phenylindole (2.5 mM; used to assess and exclude non-viable cells). Cell samples were analysed by flow cytometry using an LSR-II cytometer equipped with FACSDiVa software (Becton Dickinson, New Jersey, NY, USA), and analysed using FlowJo software (flowjo.com; Tree Star Inc., Ashland, OR, USA). Gating and evaluation of cell fractions are as described in the figure legends. Controls include comparison of staining of cell fractions from CD138À/ À mice, and evaluation of background staining using an irrelevant PE-conjugated antibody (as noted).
Bone marrow chimeras CD138 þ / þ and CD138À/À sub-populations of HSC fractions from HZ mice (CD45.1 þ ). were transferred to lethally irradiated mice, together with autologous whole bone marrow cells, to test their ability to contribute to various lineages. Specifically, bone marrow from 6-to 12-week-old donor HZ mice was flushed from femurs and tibias, and enriched for c-kit þ cells using magnetic activated-cell sorter (MACs) bead-positive selection (Miltenyi, Auburn CA, USA). The eluted cells were stained and separated based on their expression of a Lin À/lo , Kit þ , Sca1 þ and Thy1.1 lo phenotype, and further separated into two-cell fractions, one CD138 þ and the other CD138À. Two hundred HSCs of each type were injected intravenously into the retro-orbital sinus of lethally irradiated (950 rad in a split dose) C57Bl6 (CD45.2 þ ) recipients together with 3 Â 10 5 45.2 þ whole bone marrow cells. Recipients were analysed at various time points by tail vein blood draw, and donor cells from various lineages (B220, B cells; CD5, T cells; Mac-1, myeloid cells) assayed for their expression of CD45.1.
EROD assay DMBA induction of hepatic P450 CYP1A1 and 1B1 activity was measured using the ethoxyresorufin O-deethylase (EROD) assay. Twelve-day-old male mice (4-5 mice per group) were injected intraperitoneally with 0.01 or 0.1 mmol/g DMBA. After 48 h, the left liver lobe was dissected and used to prepare hepatic microsomes as described (Bunger et al., 2003) , with modifications (EROD activity (expressed as V max /ng protein) was measured in 25-50 ml of microsomes in 220 ml MENG buffer).
Statistics
All statistics were performed using Mstat 4.0. (Norman Drinkwater, McArdle Laboratory). Differences in tumor multiplicity were tested using a two-sided Wilcoxon ranksum test; differences in tumor incidence were tested using a two-sided w 2 test; differences in survival were determined using a log-rank test and graphed on a Kaplan-Meier survival curve. Tumor multiplicity was calculated as the total number of tumors divided by the number of mice. Error bars shown are standard error of the mean.
Abbreviations
Sdc1(CD138), syndecan-1; DMBA, 7, anthracene; Ahr, aryl hydrocarbon receptor; MMTV, mouse mammary tumor virus; EROD, ethoxyresorufin O-deethylase; HSCs, hematopoietic stem cells; ENU, N-ethyl-N-nitrosurea. Paraffin sections were immunostained for Keratin 8 (K8, luminal) and Keratin 5 (K5, myoepithelial), or for Mucin-1 (MUC1, luminal) and smooth muscle actin (SMA, myoepithelial), or for Keratin 10 (squamous differentiation). Tumors arising in control BALB/c mice were cystic adenocarcinomas (a, c, e, g), whereas those in Sdc1À/À mice were adenoacanthomas (b, d, f, h) . The fraction of cells (% positive) that expressed these markers is shown (Muc1, SMA, double positive (DP) or double negative (DN); averages (7s.e.m.) for five Sdc1 þ / þ cystic (Dunn type C) and eight Sdc1À/À squamous (adenoacanthomas). 
